Company intelligence / Profile preview

nib

Turin, Piedmont, Italynib.org ↗

Ownership: Private
Development stage: Other

Overview

NIB biotec develops innovative non-invasive in vitro diagnostic tests using proprietary biomarker discovery methods to enable early detection of cancers such as prostate cancer. The company has received recognition as an emerging European medtech/biotech startup but has not yet reported late-stage clinical results or commercial launches.

Therapeutic areas: Oncology
Modalities: In vitro diagnostic test (IVD)Biomarker-based diagnostics
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on nib.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nib.

Explore the full profile